Journal For Clinical Studies
Journal For Clinical Studies

SEARCH

MEDIA PACK
NEWS

MENU

Current Edition

 
aTTP

Ablynx has announced additional results from the Phase III Hercules study with caplacizumab

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the Company’s anti-von Willebrand factor (vWF) …

13 December 2017 news aTTP hematology
Continue Reading →
 
jcs-white

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Twitter Linkedin
Journal For Clinical Studies © 2022, All Rights Reserved – Powered by Teksyte